High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190 PURPOSE: To characterize the pharmacokinetics of topotecan in a population model that ...
Bioavailability of the hedgehog pathway inhibitor GDC-0449 in a phase I pharmacokinetic (PK) study in healthy female subjects. Background: Serdemetan is a compound that can cause replicative stress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results